IRVINE, Calif., Aug. 8, 2011 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has received its Clinical Laboratory Permit from the New York State Department of Health. The permit allows the Company to immediately begin receiving specimens for DNAarray™ Postnatal Developmental Testing. The DNAarray tests are based on aCGH technology, which provides physicians with a comprehensive genomic evaluation for individuals with disorders ranging from autism to mental retardation and birth defects.
